Literature DB >> 18054154

CXCL14 expression and potential function in pancreatic cancer.

Moritz N Wente1, Christine Mayer, Matthias M Gaida, Christoph W Michalski, Thomas Giese, Frank Bergmann, Nathalia A Giese, Markus W Büchler, Helmut Friess.   

Abstract

CXC chemokines influence angiogenesis, growth, and metastatic potential of pancreatic cancer. Therefore, the expression and potential function of CXCL14, a recently described CXC chemokine, was evaluated. CXCL14 is upregulated in pancreatic cancer tissues compared to chronic pancreatitis and normal pancreas. Immunolocalization revealed a distinct expression of CXCL14 in tubular complexes in chronic pancreatitis and in particular at the invasive front of pancreatic cancer tissues. Stimulation of pancreatic cancer cells with CXCL14 showed no effects on cell viability and on chemosensitivity. However, CXCL14 clearly increased invasiveness of pancreatic cancer cells without affecting MMP-2 and VEGF secretion, whereas CXCL14 influenced NFkB p65 levels. In conclusion, CXCL14 might play a pivotal role in the pathobiology of pancreatic cancer, probably by regulating cancer invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054154     DOI: 10.1016/j.canlet.2007.10.021

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

1.  Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]

Authors:  Kazuhito Izukuri; Kenji Suzuki; Nobuyuki Yajima; Shigeyuki Ozawa; Shin Ito; Eiro Kubota; Ryu-Ichiro Hata
Journal:  Transgenic Res       Date:  2010-03-24       Impact factor: 2.788

2.  Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections.

Authors:  M M Gaida; F Günther; C Wagner; H Friess; N A Giese; J Schmidt; G M Hänsch; M N Wente
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

Review 3.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling.

Authors:  Jinchang Lu; Guohui Song; Qinglian Tang; Changye Zou; Feng Han; Zhiqiang Zhao; Bicheng Yong; Junqiang Yin; Huaiyuan Xu; Xianbiao Xie; Tiebang Kang; YingLee Lam; Huiling Yang; Jingnan Shen; Jin Wang
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

5.  Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration.

Authors:  Tingting Li; Bingbing Wan; Jian Huang; Xuegong Zhang
Journal:  Mol Genet Genomics       Date:  2010-04-01       Impact factor: 3.291

6.  IRX1 hypermethylation promotes heart failure by inhibiting CXCL14 expression.

Authors:  Longhuan Zeng; Nanyuan Gu; Jiayi Chen; Guangyong Jin; Yongke Zheng
Journal:  Cell Cycle       Date:  2019-10-22       Impact factor: 4.534

7.  Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.

Authors:  Baoping Cao; Yunsheng Yang; Yuanming Pan; Yan Jia; Malcolm V Brock; James G Herman; Mingzhou Guo
Journal:  Discov Med       Date:  2013-10       Impact factor: 2.970

8.  Spatiotemporal expression and functional implication of CXCL14 in the developing mice cerebellum.

Authors:  Cho Rong Park; Dong-Kyu Kim; Eun Bee Cho; Dong-Joo You; Jean Luc do Rego; David Vaudry; Woong Sun; Hyun Kim; Jae Young Seong; Jong-Ik Hwang
Journal:  Mol Cells       Date:  2012-07-26       Impact factor: 5.034

9.  CCL20/CCR6 expression profile in pancreatic cancer.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Pirus Ghadjar; Mathias Wagner; Henner Grimm; Benjamin Vicinus; Christoph Justinger; Stefan Graeber; Martin K Schilling
Journal:  J Transl Med       Date:  2010-05-10       Impact factor: 5.531

10.  Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism.

Authors:  Helene Pelicano; Weiqin Lu; Yan Zhou; Wan Zhang; Zhao Chen; Yumin Hu; Peng Huang
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.